Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES INITIAL PUBLIC OFFERING

 PERSEPTIVE BIOSYSTEMS ANNOUNCES INITIAL PUBLIC OFFERING
 CAMBRIDGE, Mass., May 29 /PRNewswire/ -- PerSeptive Biosystems, Inc. announced today that it has commenced an initial public offering of 2.5 million shares of common stock at a price of $7 per share. The shares will be quoted on the NASDAQ National Market System under the symbol PBIO. Managing underwriters for the offering are Alex. Brown & Sons Incorporated and Cowen & Company. The company has granted the underwriters an option to purchase an additional 375,000 shares to cover over-allotments.
 PerSeptive Biosystems(R) designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 The company's products include a line of POROS(R) consumable chromatography columns and media used to perform Perfusion Chromatography and the BioCAD(tm) Workstation, a computer-aided instrumentation system designed to achieve the optimal use of the company's POROS chromatography media for laboratory and development- scale purification and for analysis.
 Prospectuses may be obtained from Alex. Brown & Sons Incorporated, 135 E. Baltimore St. Baltimore, Md. 21202, Attn: David DePietro; or Cowen & Company, Financial Square, 27th Floor, New York, N.Y. 10005, Attn: Jack Dumphy.
 This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 PerSeptive Biosystems, Perfusion Chromatography and POROS are registered trademarks and BioCAD, ImmunoDetection and Rational Surface Design are trademarks of the company.
 -0- 5/29/92
 /CONTACT: James E. Coutre, president and CEO of PerSeptive Biosystems, 617-621-1787; or Robert Gottlieb of Feinstein Partners, Inc., 617-577-8110, for PerSeptive Biosystems/ CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU: OFR


CN -- NE006 -- 5176 05/29/92 12:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 29, 1992
Words:355
Previous Article:THE CHARTER COMPANY'S SPELLING ENTERTAINMENT INC. SUBSIDIARY ANNOUNCES SIX NETWORK SERIES
Next Article:LOUIS G. LENZI NAMED GENERAL COUNSEL OF MBIA INC.
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THE EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 375,000 SHARES, COMPLETING ITS INITIAL PUBLIC OFFERING
PERSEPTIVE BIOSYSTEMS SUBMITS DRUG MASTER FILE WITH FDA COVERING POROS CHROMATOGRAPHY MEDIA
PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
PERSEPTIVE BIOSYSTEMS NAMES HUBERT M. QUINN VICE PRESIDENT, CHEMICAL PRODUCTION
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS SIGN FINAL AGREEMENT TO FORM PERISIS
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PERSEPTIVE BIOSYSTEMS ANNOUNCES FILING OF REGISTRATION STATEMENT RELATING TO PERSEPTIVE TECHNOLOGIES II CORP.
PERSEPTIVE BIOSYSTEMS CREATES NEW EXECUTIVE POST
PERSEPTIVE BIOSYSTEMS COMMENCES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION
PERSEPTIVE BIOSYSTEMS ANNOUNCES PLANNED STAFF REDUCTIONS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters